Salvatore Petta
#165,034
Most Influential Person Now
Researcher
Salvatore Petta's AcademicInfluence.com Rankings
Salvatore Pettaengineering Degrees
Engineering
#7267
World Rank
#8631
Historical Rank
Electrical Engineering
#2252
World Rank
#2358
Historical Rank
Salvatore Pettacomputer-science Degrees
Computer Science
#9824
World Rank
#10306
Historical Rank
Computational Linguistics
#2421
World Rank
#2445
Historical Rank
Machine Learning
#4401
World Rank
#4451
Historical Rank
Artificial Intelligence
#4755
World Rank
#4818
Historical Rank
Download Badge
Engineering Computer Science
Salvatore Petta's Degrees
- Masters Electrical Engineering Stanford University
- Bachelors Computer Engineering University of California, Berkeley
Why Is Salvatore Petta Influential?
(Suggest an Edit or Addition)Salvatore Petta's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) (881)
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
- Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. (2012) (609)
- The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. (2016) (476)
- Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C (2010) (465)
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) (426)
- Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease (2015) (424)
- Statin use and non-alcoholic steatohepatitis in at risk individuals. (2015) (288)
- Non-alcoholic fatty liver disease pathogenesis: the present and the future. (2009) (282)
- Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. (2021) (277)
- Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. (2018) (271)
- Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. (2018) (271)
- AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. (2017) (243)
- Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. (2019) (233)
- Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice (2015) (223)
- Comparison of Transient Elastography and Acoustic Radiation Force Impulse for Non-Invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C (2011) (210)
- Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver (2017) (210)
- Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort. (2020) (202)
- The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease (2015) (200)
- Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection (2008) (199)
- Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. (2016) (192)
- MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals (2017) (180)
- Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values (2017) (174)
- Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation (2020) (171)
- Advancing the global public health agenda for NAFLD: a consensus statement (2021) (167)
- Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease (2017) (148)
- Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index (2011) (141)
- Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. (2015) (139)
- Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity (2017) (135)
- Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study (2017) (133)
- Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores (2020) (133)
- Hyperuricemia is associated with histological liver damage in patients with non‐alcoholic fatty liver disease (2011) (132)
- Cost‐effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C (2012) (132)
- The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease (2015) (129)
- Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD (2017) (128)
- Pathophysiology of Non Alcoholic Fatty Liver Disease (2016) (125)
- Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations (2012) (121)
- Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease (2014) (115)
- Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis (2020) (112)
- Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1 (2010) (110)
- Visceral adiposity index is associated with significant fibrosis in patients with non‐alcoholic fatty liver disease (2012) (109)
- Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. (2011) (103)
- Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. (2017) (101)
- Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis (2021) (100)
- MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. (2016) (98)
- Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. (2018) (97)
- Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease. (2020) (94)
- Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection (2011) (91)
- Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. (2018) (90)
- The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage (2016) (90)
- IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. (2012) (90)
- Cost‐effectiveness of sofosbuvir‐based triple therapy for untreated patients with genotype 1 chronic hepatitis C (2014) (89)
- Development and Validation of Hepamet Fibrosis Scoring System-a Simple, Non-invasive Test to Identify Patients With Nonalcoholic Fatty liver Disease With Advanced Fibrosis. (2019) (86)
- Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis (2009) (84)
- Hepatitis C and diabetes: the inevitable coincidence? (2009) (82)
- The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C (2007) (82)
- Cost‐effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma (2013) (82)
- Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon (2017) (81)
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. (2021) (80)
- Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. (2019) (80)
- Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease (2017) (79)
- Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. (2013) (79)
- Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. (2017) (77)
- Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease (2019) (77)
- Reproductive Status Is Associated with the Severity of Fibrosis in Women with Hepatitis C (2012) (76)
- PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease (2013) (75)
- Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. (2014) (74)
- Anti-Tissue Transglutaminase Antibodies in Patients with Abnormal Liver Tests: Is It Always Coeliac Disease? (2005) (74)
- Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network (2017) (74)
- Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease (2019) (73)
- Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? (2021) (72)
- The membrane‐bound O‐acyltransferase domain‐containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B (2017) (68)
- A "systems medicine" approach to the study of non-alcoholic fatty liver disease. (2016) (68)
- Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population (2018) (68)
- A meta‐analysis of single HCV‐untreated arm of studies evaluating outcomes after curative treatments of HCV‐related hepatocellular carcinoma (2017) (68)
- Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. (2010) (67)
- Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. (2020) (66)
- Genetic background in nonalcoholic fatty liver disease: A comprehensive review. (2015) (65)
- Cardiovascular diseases and HCV infection: a simple association or more? (2013) (65)
- Retinol‐binding protein 4: A new marker of virus‐induced steatosis in patients infected with hepatitis c virus genotype 1 (2008) (65)
- Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease (2016) (61)
- Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. (2019) (61)
- Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. (2013) (60)
- Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis (2015) (60)
- Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients (2019) (57)
- Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients (2013) (56)
- Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study (2020) (56)
- Exome-wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated with Fatty Liver Disease. (2020) (55)
- An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. (2018) (54)
- Recurrence of hepatocellular carcinoma after liver transplantation: an update. (2015) (50)
- Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS (2017) (49)
- Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. (2021) (48)
- qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis (2020) (47)
- Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease. (2020) (46)
- The UCP2 ‐866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. (2015) (43)
- Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. (2013) (43)
- HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct‐acting antivirals (2018) (42)
- Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease (2017) (42)
- Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? (2018) (42)
- The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. (2020) (42)
- Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease (2015) (40)
- Current and future HCV therapy: do we still need other anti‐HCV drugs? (2015) (40)
- Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2017) (40)
- Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age‐dependent risk profiling study (2017) (40)
- Is global elimination of HCV realistic? (2018) (38)
- Evaluating the association of serum ferritin and hepatic iron with disease severity in non‐alcoholic fatty liver disease (2019) (38)
- Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease (2018) (37)
- Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. (2019) (37)
- The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives (2019) (36)
- PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients[S] (2019) (36)
- Hepatitis C virus and cardiovascular: A review (2016) (35)
- Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals (2019) (35)
- Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. (2021) (35)
- Serum coding and non‐coding RNAs as biomarkers of NAFLD and fibrosis severity (2019) (35)
- Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study (2018) (34)
- Metabolic Factors and Chronic Hepatitis C: A Complex Interplay (2013) (34)
- Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver (2020) (34)
- NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis (2013) (34)
- Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. (2019) (33)
- Transrectal colour Doppler contrast sonography in the diagnosis of local recurrence after radical prostatectomy--comparison with MRI. (2006) (33)
- Vitamin D Levels and Il28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C (2012) (32)
- Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C (2013) (31)
- Serum γ-glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases (2012) (31)
- Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. (2013) (30)
- Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? (2013) (29)
- The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. (2015) (29)
- High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. (2011) (28)
- The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease (2016) (28)
- Machine Perfusions in Liver Transplantation: The Evidence‐Based Position Paper of the Italian Society of Organ and Tissue Transplantation (2020) (27)
- Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis (2009) (27)
- Optimization of hepatitis C virus screening strategies by birth cohort in Italy (2020) (26)
- TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1 (2011) (26)
- Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. (2021) (24)
- Impact of virus eradication in patients with compensated hepatitis C virus‐related cirrhosis: competing risks and multistate model (2016) (23)
- TM6SF2 Gene Variant Disentangles Nonalcoholic Steatohepatitis from Cardiovascular Disease (2014) (23)
- Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis (2015) (23)
- Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. (2009) (23)
- MAFLD vs NAFLD: Let the contest begin! (2020) (23)
- The cheating liver: imaging of focal steatosis and fatty sparing (2016) (23)
- Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future. (2009) (22)
- Sarcopenia is Associated with Severe Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease (2016) (22)
- How to optimize HCV therapy in genotype 1 patients: predictors of response (2013) (22)
- PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non‐obese subjects with hepatitis C (2015) (21)
- Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. (2013) (20)
- Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection (2009) (19)
- Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C (2008) (19)
- Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with non‐alcoholic fatty liver: An external validation study (2018) (18)
- Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study (2018) (18)
- Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection (2012) (18)
- Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity (2019) (18)
- Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. (2017) (17)
- A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B (2018) (17)
- Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. (2020) (17)
- Rare ATG7 genetic variants predispose patients to severe fatty liver disease. (2022) (17)
- First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials (2021) (16)
- Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives (2019) (16)
- From current status to optimization of HCV treatment: Recommendations from an expert panel. (2016) (16)
- Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. (2020) (16)
- Geographical similarity and differences in the burden and genetic predisposition of NAFLD (2022) (15)
- PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD (2020) (15)
- TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C (2016) (15)
- Liver and Statins: A Critical Appraisal of the Evidence. (2019) (15)
- Italian association for the study of the liver position statement on SARS-CoV2 vaccination (2021) (15)
- Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance (2013) (15)
- Diet, Weight Loss, and Liver Health in NAFLD: Pathophysiology, Evidence and Practice (2015) (14)
- Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. (2012) (14)
- Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). (2014) (14)
- Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease (2019) (14)
- Prevalence, predictors and severity of lean non-alcoholic fatty liver disease in HIV-infected patients. (2020) (14)
- Is there an ‘ideal’ diet for patients with NAFLD? (2021) (14)
- High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C (2013) (13)
- Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. (2020) (13)
- Extrahepatic Manifestations of Chronic Viral C Hepatitis. (2020) (13)
- Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. (2016) (13)
- Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? (2012) (12)
- Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients (2012) (12)
- Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease (2020) (12)
- Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. (2012) (12)
- Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis (2020) (12)
- Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. (2013) (11)
- Optimal therapy in hepatitis C virus genotypes 2 and 3 patients (2011) (11)
- Methylenetetrahydrofolate reductase homozygosis and low‐density lipoproteins in patients with genotype 1 chronic hepatitis C (2012) (11)
- Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. (2013) (11)
- IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection (2016) (11)
- Outcomes of Liver Transplant for Adults With Wilson’s Disease (2020) (10)
- Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV‐monoinfected patients (2020) (10)
- Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort (2018) (10)
- Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography (2020) (10)
- FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage (2020) (9)
- Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice (2015) (9)
- Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance (2021) (9)
- PSD3 downregulation confers protection against fatty liver disease (2022) (9)
- Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis (2018) (9)
- Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease (2022) (9)
- Management of liver disease in Italy after one year of the SARS‐CoV‐2 pandemic: A web‐based survey (2021) (9)
- Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. (2014) (9)
- Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors? (2012) (8)
- Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus (2021) (8)
- Lifestyle changes for the treatment of nonalcoholic fatty liver disease - A 2015-19 update. (2020) (8)
- AGILE 3+ Score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. (2022) (8)
- PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Non-alcoholic Fatty Liver Disease. (2020) (8)
- Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons with HIV infection and Compensated Advanced Chronic Liver Disease. (2019) (8)
- Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. (2020) (8)
- HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study (2016) (8)
- Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. (2020) (7)
- 751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS (2008) (7)
- Point‐of‐care HCV RNA testing in the setting of DAA therapy: HCV‐FiS (HEpatitis C Virus Fingerstick Study) (2019) (7)
- Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis (2022) (7)
- Coffee and tea breaks for liver health. (2017) (7)
- Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort (2021) (7)
- Expert Opinion on Managing Chronic HCV in Patients with Cardiovascular Disease (2018) (7)
- AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. (2020) (6)
- Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. (2014) (6)
- Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe? (2012) (6)
- Performance of the PROC 3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease (2019) (6)
- 1360 PNPLA3 GG GENOTYPE IS ASSOCIATED WITH CAROTID ATHEROSCLEROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (2013) (6)
- Hepamet Score: a new non-invasive method for NAFLD-related fibrosis screening in clinical practice (2018) (5)
- Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals (2017) (5)
- Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs) (2017) (5)
- Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'. (2016) (5)
- Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. (2020) (5)
- Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis (2015) (5)
- Protein Phosphatase 1 Regulatory Subunit 3 B Gene Variation Protects Against Hepatic Fat Accumulation and Fibrosis in Individuals at High Risk of Nonalcoholic Fatty Liver Disease (2018) (5)
- Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). (2020) (4)
- Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus (2020) (4)
- PS-200-The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD (2019) (4)
- Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). (2021) (4)
- PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients patient-oriented and epidemiological research (2020) (4)
- Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH) (2021) (4)
- Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators (2022) (4)
- Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients (2021) (4)
- MAFLD: a multisystem disease (2023) (4)
- Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). (2021) (4)
- Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). (2021) (4)
- Evidence-Based Medicine and the Problem of Healthy Volunteers. (2017) (3)
- Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. (2020) (3)
- AISF position paper on HCV in immunocompromised patients (2019) (3)
- NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease (2021) (3)
- FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver (2019) (3)
- Reply to: "IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients". (2013) (3)
- F-31Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs) (2017) (3)
- Substantial variability of the diagnostic accuracy of serum fibrosis markers across multiple cohorts of nash patients in various centers : the case for the negative predictive value (2015) (3)
- The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. (2020) (3)
- Epicardial fat in patients with non-alcoholic fatty liver disease. (2015) (3)
- P0340 : Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): A multicenter case-control study (2015) (3)
- Genetic variants in the MTHFR are not associated with fatty liver disease (2020) (3)
- FibroScan Detects Cardiovascular Damage in Patients With NAFLD. (2018) (3)
- Interplay between non‐alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population (2021) (3)
- Evidence-Based Medicine and the Problem of Healthy Volunteers. (2017) (3)
- HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study (2016) (3)
- 1174 LOW VITAMIN D SERUM LEVEL IS RELATED TO RAPID, EARLY AND SUSTAINED VIROLOGICAL RESPONSE TO IFN-BASED THERAPY IN GENOTYPE 1 CHRONIC HEPATITIS C (2011) (2)
- Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): a multicenter case-control study (2015) (2)
- PS-205-Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease: An international study in non-cirrhotic, biopsy-proven patients (2019) (2)
- Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis. (2022) (2)
- Dual proteotoxic stress accelerates liver injury via activation of p62‐Nrf2 (2021) (2)
- Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry (2017) (2)
- MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver (2016) (2)
- Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection (2008) (2)
- Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial. (2022) (2)
- OC-6 Vitamin D serum level and IL28B rs12979860 polymorphism are related to rapid virological response to IFN-based therapy in genotype 1 chronic hepatitis C (2011) (2)
- Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease (2020) (2)
- High rate of misclassification of fibrosis stage using transient elastography thresholds to prioritize HCV patients for antiviral treatment (2017) (2)
- Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort"☆ (J Hepatol [2020] 505-515). (2021) (2)
- Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study (2021) (2)
- A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification (2020) (2)
- A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease (2022) (2)
- Can we prevent and modify cardiometabolic disorders by controlling HCV infection? (2017) (2)
- Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease (2017) (2)
- “Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV” (2022) (2)
- SAT-223-AA genotype of the deSNP rs6726639 of gene MERTK (MER Tyrosine Kinase) is associated with development of hepatocellular carcinoma after hepatitis C virus clearance (2019) (1)
- PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT (2019) (1)
- Aminopyrine breath test predicts liver‐related events and death in HCV‐related cirrhosis on SVR after DAA therapy (2020) (1)
- Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update". (2021) (1)
- RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study (2022) (1)
- 412 INSULIN RESISTANCE SIGNIFICANTLY CONTRIBUTE TO LIVER STIFFNESS IN NONDIABETIC PATIENTS WITH GENOTYPE 1 HCV INFECTION (2009) (1)
- Serum BLyS/BAFF levels in acute hepatitis C predict clinical outcome (2008) (1)
- Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease (2020) (1)
- Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. (2022) (1)
- Poster SessionsThursday, February 21stT-03 Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients (2013) (1)
- How to improve patients' adherence to treatment of hepatitis C with protease inhibitors (2013) (1)
- PC.01.8: PTPN2 RS2542151 G->T Polymorphism is Associated with Type 2 Diabetes Mellitus and Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) (2017) (1)
- PostersPoster Session – Saturday, April 21, 201210b. Fatty Liver Disease: Clinical1315 IL28B AND PNPLA3 POLYMORPHISMS AFFECT HISTOLOGICAL LIVER DAMAGE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (2012) (1)
- Corrigendum to "Coffee and tea breaks for liver health" [J Hepatol 67 (2017) 221-223]. (2017) (1)
- 473 ASSOCIATION OF VITAMIN D SERUM LEVELS AND ITS COMMON GENETIC DETERMINANTS, WITH SEVERITY OF LIVER FIBROSIS IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2013) (1)
- P162 Prevalence of nafld (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, intestinal inflammation and genetic phenotype (2020) (1)
- Europe’s largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4) (2020) (1)
- Small intestinal bacterial overgrowth: A new face of irritable bowel syndrome? (2006) (1)
- FibroScan stiffness and CAP in the evaluation of cardiovascular risk assessment in patients with NAFLD (2018) (1)
- Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy (2010) (1)
- The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI (2020) (1)
- Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirhhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry (2017) (1)
- Mer Tyrosine Kinase (MERTK) modulates liver fibrosis progression and hepatocellular carcinoma development (2022) (1)
- FNDC5 rs3480 A>G polymorphism disentangles steatosis from fibrosis severity in patients with nonalcoholic fatty liver disease (2016) (1)
- Visceral adiposity index and exercise in non‐alcoholic fatty liver disease: authors’ reply (2012) (1)
- The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries (2020) (1)
- Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. (2023) (1)
- Variant is Associated with Liver Damage in Patients with Non-alcoholic Fatty Liver Disease (2017) (1)
- O071 : Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash (2015) (1)
- Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis (2017) (1)
- Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation (2022) (1)
- Characterizing compensated cirrhosis (CC) patients with potential etiology of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH): findings from large Italian administrative databases (2019) (1)
- Biochemical Biomarkers of NAFLD/NASH (2020) (1)
- Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease (2020) (1)
- Role of the protein tyrosine kinase Mer (MerTK) in the cross-talk between macrophages and hepatic stellate cells (2018) (1)
- 486 INDUSTRIAL, BUT NOT FRUIT FRUCTOSE INTAKE IS INDEPENDENTLY ASSOCIATED WITH SEVERE LIVER FIBROSIS IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2013) (1)
- Hepatocyte depletion of ERK5 impairs the response to lipotoxic oxidative stress resulting in defective insulin receptor signaling (2023) (0)
- 658 HCV CONTRIBUTES TO INDUCE HEPATIC STEATOSIS DEREGULATING LIPID METABOLISM THROUGH LXR DEPENDING GENES MODULATION (2010) (0)
- Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. (2021) (0)
- Personalized platelets/liver stiffness ratio improves and secures the screening of esophageal varices needing treatment (2020) (0)
- [Hepatitis C virus infections: is it only e liver disease?] (2018) (0)
- 614 Kinetic analysis of insulin resistance and serum adipocytokines levels during peginterferon alpha-2A plus ribavirin therapy in non-diabetic HCV patients (2006) (0)
- Changes in 13C-aminopyrine breath test predict liver-related events and death in patients with HCV-related previous decompensated child A5 or child A6 to B cirrhosis who achieve SVR after DAA therapy (2019) (0)
- PNPLA3 Rs738409 C>G Variant Predicts Liver-Related Outcomes in Patients with Non-Alcoholic Fatty Liver Disease (2019) (0)
- Reply (2015) (0)
- ATG7 genetic variant and defective autophagy: a novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus (2019) (0)
- OC.03.2 ASSOCIATION OF VITAMIN D SERUM LEVELS AND ITS COMMON GENETIC DETERMINANTS, WITH SEVERITY OF LIVER FIBROSIS IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2013) (0)
- Individual and population screening of varices needing treatment by a simple, safe and accurate test. (2023) (0)
- Could controlled attenuated parameter be useful to improve the diagnostic accuracy of liver stiffness measurement for staging fibrosis in non‐alcoholic fatty liver disease? (2015) (0)
- RESIST-HCV criteria are able to rule out esophageal varices progression in patients with HCV cirrhosis treated by Direct-acting Antiviral Agents(DAAs) (2021) (0)
- P817 EARLY MENOPAUSAL STATUS IS ASSOCIATED WITH THE SEVERITY OF LIVER FIBROSIS IN ITALIAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (2014) (0)
- OXYSTEROLS PLASMA LEVELS CORRELATE WITH CHRONIC LIVER DISEASES (2008) (0)
- PS-095-MerTK-mediated cytokine secretion mediates a cross-talk between M2c macrophages and hepatic stellate cells to induce fibrosis (2019) (0)
- P1013 : Chronic intermittent hypoxia is associated with liver damage and atherosclerosis in patients with non-alcoholic fatty liver disease (2015) (0)
- Insulin Resistance in Prediction of Esophageal Varices. Authors' reply (2009) (0)
- LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS (2011) (0)
- HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy (2018) (0)
- Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease". (2018) (0)
- P1030 : The presence of white matter lesions is not associated with non-alcoholic fatty liver disease but with its histological severity (2015) (0)
- Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis (2008) (0)
- Response to Dr Karlas and colleagues. (2017) (0)
- Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?". (2014) (0)
- Reply: To PMID 22135089. (2013) (0)
- The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance (2018) (0)
- T-18 Liver follicular helper T-cells in chronic hepatitis C (2011) (0)
- GEMS, a GEnetic and Metabolic Staging predicting the outcome of non-alcoholic fatty liver disease (2021) (0)
- Emerging increase in the prevalence and severity of nonalcoholic fatty liver disease: Epidemiological study from general Mediterranean population (2016) (0)
- Role of the receptor tyrosine kinase MER in the development of fibrosis in NAFLD (2015) (0)
- Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis (2018) (0)
- Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. (2023) (0)
- P0912 : Early-phase HCV kinetics and role of pre-existing resistance in cirrhotic or interferon-insensitive patients on daclatasvir plus asunaprevir (2015) (0)
- Long-Term Clinical and Prognostic Significance of Serum Antinuclear Autoantibodies in Patients with Non-Alcoholic Fatty Liver Disease (2020) (0)
- Liver stiffness quantification in patients with non-alcoholic steatohepatitis: comparison of shear wave elastography and transient elastography with liver biopsy correlation (2019) (0)
- Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH) (2018) (0)
- F-06 Industrial, but not fruit fructose intake is independently associated with severe liver fibrosis in genotype 1 chronic hepatitis C patients (2013) (0)
- P768 PNPLA3 rs738409 C>G SNP IS ASSOCIATED WITH HISTOLOGICAL FEATURES OF NASH IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2014) (0)
- SAT-078-Characterizing compensated cirrhosis patients with potential etiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Findings from large Italian administrative databases (2019) (0)
- PCSK9 rs11591147 R46L Loss-of-Function Variant Protects Against Liver Damage in Individuals with NAFLD (2020) (0)
- T06.01.23 STEATOSIS AS A PREDICTIVE MARKER OF CARDIOVASCULAR ALTERATIONS IN A MEDITERRANEAN PRIMARY CARE COHORT (2020) (0)
- High-throughput RNA sequencing unravels pathways associated with the progression of non-alcoholic liver disease (2017) (0)
- Update on treatment strategies in patients with non-alcoholic fatty liver disease. (2013) (0)
- PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with non-alcoholic fatty liver (2020) (0)
- Rare and common ATG7 variants predispose to severe fatty liver disease (2021) (0)
- Increased serum ferritin levels predict long-term mortality in patients with NAFLD (2021) (0)
- The histological or ultrasonographic detection of steatosis affects the performance of LSM in patients with chronic HCV genotype 1 infection (2014) (0)
- Diagnostic performance of AGILE 3+ score for identification of advanced fibrosis and prediction of liver-related events in patients with non-alcoholic fatty liver disease (2022) (0)
- Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease (2019) (0)
- A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease (2020) (0)
- Paper alert. (2022) (0)
- A Cholestatic Pattern Predicts Liver-Related Events in Patients with Nonalcoholic Fatty Liver Disease (2021) (0)
- Integrative analysis of NGS data highlight a genetic variant in ATG7 gene as a novel risk factor for nonalcoholic fatty liver disease progression (2018) (0)
- FRI-333-ATG7 genetic variant and defective autophagy: A novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus (2019) (0)
- Hepatitis C treatment with a focus on HCV protease inhibitors (Part Two) (2013) (0)
- Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study (2020) (0)
- 389 LONG-TERM EVALUATION OF FIBROSIS BY TRANSIENT ELASTOGRAPHY IN PATIENTS CLEARING HCV ON ANTIVIRAL THERAPY (2010) (0)
- Mo1448 OBETICHOLIC ACID IMPROVES TRANSAMINASES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE 18-MONTH INTERIM ANALYSIS OF THE REGENERATE STUDY (2020) (0)
- The proto-oncogene tyrosine-protein kinase MER as a novel modulator of fibrogenesis in NAFLD (2015) (0)
- AF.81 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL (2021) (0)
- STAT4 variants increase liver fibrosis risk in chronic hepatitis B through impaired STAT4- dependent NK cell IFN-γ production (0)
- The Role of Transient Elastography in NAFLD (2021) (0)
- Is liver stiffness measurement unreliable in obese patients? authors’ reply (2011) (0)
- Current epidemiology of HCV in Sicily: the RESIST-HCV model (2019) (0)
- Risk of hepatocellular carcinoma recurrence in hepatitis C cirrhotic patients treated with direct acting antivirals (2017) (0)
- T06.01.19 THE ECONOMIC COST AND HEALTH BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS IN THE EU5 COUNTRIES (2020) (0)
- T.N.33 HCV CONTRIBUTES TO INDUCE HEPATIC STEATOSIS THROUGH NUCLEAR LXR RECEPTOR (2010) (0)
- Steatohepatitis and type 2 diabetes mellitus are influenced by genetic susceptibility to increased intestinal permeability in patients with non-alcoholic fatty liver disease (2017) (0)
- Effects of HCV eradication by DAA on oxidative stress parameters in patients with chronic hepatitis C (2019) (0)
- Normal Values of Liver Stiffness as Measured by Transient Elastography: Pooled Individual Participant Data Meta-Analysis from 26 Studies and 14,883 Participants (2017) (0)
- Author response for "Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antivirals therapy. A prospective study" (2020) (0)
- Impact of obesity, insulin resistance and hyperandrogenism on steatosis and fibrosis risk in young females with PCOS (2017) (0)
- Reply: (2008) (0)
- Impact of non-alcoholic fatty liver disease on cardiovascular risk in a general population (2020) (0)
- Early menopausal status is associated with the severity of liver fibrosis in Italian patients with non-alcoholic fatty liver disease (2014) (0)
- New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: Evaluation by controlled attenuation parameter (CAP) and liver stiffness measurement LSM (2021) (0)
- Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance (2020) (0)
- T04.01.11 PREVALENCE OF NAFLD (NON ALCOHOLIC FATTY LIVER DISEASE) IN INFLAMMATORY BOWEL DISEASE: THE IMPACT OF TRADITIONAL RISK FACTORS, INTESTINAL INFLAMMATION AND GENETIC PHENOTYPE (2020) (0)
- T-20 Visceral adiposity index, expression of adipose dysfunction, is associated with significant fibrosis in patients with non-alcoholic fatty liver disease (2011) (0)
- T-6 Hyperuricemia is associated with severe steatosis in patients with chronic hepatitis C (2012) (0)
- Determinants of liver stiffness measurements in patients with NAFLD-an individual patient data meta-analysis (2022) (0)
- Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization (HCRU) and costs: results from Italian administrative databases (2019) (0)
- Glycemic control, body weight reduction, or glucose-lowering therapy in diabetic patients: What is better for the liver? (2023) (0)
- PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES (2019) (0)
- Reply (2017) (0)
- PNPLA3 rs738409 C>G variant predicts occurrence of liver-related events and death in non-alcoholic fatty liver (2019) (0)
- Reply (2013) (0)
- MerTK-mediated cytokine secretion mediates a cross-talk between M2c macrophages and hepatic stellate cells (HSC) to induce fibrosis (2019) (0)
- Rare Atg7 Genetic Variants Predispose to Severe Fatty Liver Disease (2021) (0)
- Title: PNPLA3 rs738409 I748M Variant and Histological Features of Nonalcoholic Steatohepatitis in Patients with Genotype 1 Chronic Hepatitis C SHORT TITLE: PNPLA3 AND NASH IN CHRONIC HEPATITIS C AUTHORS: (0)
- T-5 High sCD36 plasma level is associated with steatosis and its severity in patients with chronic genotype 1 hepatitis C (2012) (0)
- THU-334-PNPLA3 rs738409 C >G variant predicts liver-related events and death in non-alcoholic fatty liver (2019) (0)
- Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort (2019) (0)
- OC-11 PNPLA3 GG genotype is associated with carotid atherosclerosis in patients with non-alcoholic fatty liver disease (2013) (0)
- OC.07.4 HCV PATIENTS ARE FEATURED BY AN INVERSE CORRELATION BETWEEN OXYSTEROLS PLASMA LEVELS AND LDL-CHOLESTEROL (2012) (0)
- AF.87 RESIST-HCV CRITERIA ARE ABLE TO RULE OUT ESOPHAGEAL VARICES PROGRESSION IN PATIENTS WITH HCV CIRRHOSIS TREATED BY DIRECT-ACTING ANTIVIRAL AGENTS(DAAS) (2021) (0)
- MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals (2017) (0)
- HEPATIC EXPRESSION OF CYCLOOXYGENASE-2 IN NON-ALCOHOLIC FATTY LIVER DISEASE (2008) (0)
- Virus-related insulin resistance in HCV genotype 1 chronic hepatitis C : a major disease modifier (2007) (0)
- A cholestatic pattern predicts major liver‐related outcomes in patients with non‐alcoholic fatty liver disease (2022) (0)
- THU-335-FXR rs35724 C >G variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver (2019) (0)
- PNPLA3 gene variants and insulin resistance in patients with genotype-1 chronic hepatitis C (2013) (0)
- Noninvasvie prediction of oesophageal varics by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study (2018) (0)
- SIRT5 rs12216101 T>G variant is associated with fibrosis severity in patients with non-alcoholic fatty liver disease (2021) (0)
- Reply: (2010) (0)
- THU-304-Modeling NAFLD-related disease progression among the PITER SVR12 cohort (2019) (0)
- P816 MERTK rs4374383 AA GENOTYPE IS ASSOCIATED WITH A LOWER PREVALENCE OF SEVERE HEPATIC STEATOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (2014) (0)
- Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study. (2023) (0)
- Role of rare pathogenic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease (2018) (0)
- Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease. An international study in non-cirrhotic, biopsy-proven patients (2019) (0)
- IL28B rs12979860 CC Genotype, Metabolic Profile and SVR in Patients with Genotype 1 Chronic Hepatitis C. (2012) (0)
- Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) (2017) (0)
- Functional characterization of a novel genetic variant predisposing to hepatocellular carcinoma development in nonalcoholic fatty liver disease (2018) (0)
- Increased burden of inherited IRF3 rare genetic variants in Europeans with severe Non-alcoholic fatty liver diease (2022) (0)
- Fibroscan liver stiffness (LMS) and controlled attenuation parameter (CAP) in the evaluation of cardiovascular risk assessment in patients with NAFLD (2018) (0)
- Chemoprevention for hepatocellular carcinoma: the role of statins. (2012) (0)
- Reliability criteria for the diagnosis of fatty liver using controlled attenuation parameter by transient elastography – A multicentre study of 754 patients (2017) (0)
- 480 FOLLICULAR HELPER T-CELLS POPULATE THE INTRAHEPATIC INFILTRATES OF HCV GENOTYPE-1 CHRONICALLY INFECTED PATIENTS AND PREDICT THE ACHIEVEMENT OF VIROLOGICAL RESPONSE FOLLOWING IFN-BASED TREATMENT (2011) (0)
- Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". (2014) (0)
- Noninvasive risk stratification in nonalcoholic fatty liver disease: a polygenic risk score (2020) (0)
- Reply (2016) (0)
- OC.03.4 INSULIN RESISTANCE, STEATOSIS AND PROGRESSION OF FIBROSIS IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (2010) (0)
- The presence of white matter lesions is not associated with non-alcoholic fatty liver disease but with its histological severity (2015) (0)
- The variscreen algorithm using successively platelets, liver stiffness and INR improves and secures the screening of esophageal varices needing treatment (2020) (0)
- Editorial (Hot Topic: Update on Treatment Strategies in Patients with Non-alcoholic Fatty Liver Disease) (2013) (0)
- OC-08Rare ATG7 genetic variants predispose to severe fatty liver disease (2021) (0)
- OC.09.4 PREVALENCE OF NAFLD (NON ALCOHOLIC FATTY LIVER DISEASE) IN INFLAMMATORY BOWEL DISEASE: THE ROLE OF METABOLIC FACTORS, INTESTINAL INFLAMMATION AND GENETIC PHENOTYPE (2021) (0)
- 630 SERUM BLYS/BAFF LEVELS IN ACUTE HEPATITIS C PREDICT CLINICAL OUTCOME (2008) (0)
- FNDC5 rs3480 A > G Polymorphism Disentangles Steatosis from Fibrosis Severity in Patients with Non-Alcoholic Fatty Liver Disease (2016) (0)
- OC-8 IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease (2012) (0)
- MERTK rs4374383 AA genotype is associated with a lower prevalence of severe hepatic steatosis in non-alcoholic fatty liver disease (2014) (0)
- Reply: (2009) (0)
- T-4 Thyroid-stimulating hormone serum level, liver thyroid-stimulating hormone-receptor, and severe fibrosis in genotype 1 chronic hepatitis C patients with normal thyroid function (2012) (0)
- OC.07.1 DIRECT ACTING ANTIVIRALS AFTER SUCCESSFUL TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA IMPROVE SURVIVAL AND REDUCE HEPATIC DECOMPENSATION IN HCV-CIRRHOTIC PATIENTS (2019) (0)
- PNPLA3 rs738409 C >G variant is associated with a higher risk of liver fibrosis progression assessed by FIB-4 and stiffness by fibroscan in patients with non-alcoholic fatty liver disease (2020) (0)
- Non-invasive Diagnostic Approach to NASH: Biological Markers (2020) (0)
- Heart rate variability is associated with disease severity and portal hypertension in cirrhosis (2023) (0)
- 69 SIMULTANEOUS DETERMINATION OF SPHYNGOMYELIN AND FREE CERAMIDE IN BIOLOGICAL SAMPLES BY GAS CHROMATOGRAPHY/MASS SPECTROMETRY (2008) (0)
- P0760 : PNPLA3 rs738409 I748M is associated with steatohepatitis in non obese subjects with hepatitis C (2015) (0)
- PS-061-Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization and costs: Results from Italian administrative databases (2019) (0)
- 919 THYROID-STIMULATING HORMONE SERUM LEVEL, LIVER THYROID-STIMULATING HORMONE-RECEPTOR, AND SEVERE FIBROSIS IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS WITH NORMAL THYROID FUNCTION (2012) (0)
- Genotype 1 Relapsers and Non‐Responders (2011) (0)
- Independent predictors of CC-IMT progression over time (mm/year) in 63 patients with NAFLD from Northern Italy. (2013) (0)
- Optimizing treatment duration in chronic hepatitis C on the basis of virological response (2010) (0)
- P1009 THE HISTOLOGICAL OR ULTRASONOGRAPHIC DETECTION OF STEATOSIS AFFECTS THE PERFORMANCE OF LIVER STIFFNESS MEASUREMENT FOR FIBROSIS ASSESSMENT IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION (2014) (0)
- The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. (2016) (0)
- P.05.17: The Course of Inflammatory Bowel Disease in Patients Under Treatment with Direct Antiviral Agents for Hepatitis C – A preliminary Report (2017) (0)
- Non-invasive tools to ruling out large varices: RESIST-HCV vs. Baveno VI criteria in a large cohort of patients with HCV cirrhosis (2017) (0)
- Chronic Intermittent Hypoxia is associated with Liver Damage and Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease (2015) (0)
- OC.04.3 FIRST-LINE IMMUNE CHECKPOINT INHIBITOR-BASED SEQUENTIAL THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A RATIONALE FOR FUTURE TRIALS (2021) (0)
- T-19 Higher thyroid-stimulating hormone serum level is related to severe fibrosis in genotype 1 chronic hepatitis C patients with normal thyroid function (2011) (0)
- Diagnostic accuracy of non-invasive tests for cirrhotic NASH-an individual participant data meta-analysis (2022) (0)
- Response to Eddowas and colleagues (2016) (0)
- F.N.34 LONG-TERM EVALUATION OF FIBROSIS BY TRANSIENT ELASTOGRAPHY IN PATIENTS CLEARING HCV ON ANTIVIRAL THERAPY (2010) (0)
- Noninvasive prediction of esophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study (2018) (0)
- OC-10Liver-related and extrahepatic events occurrence in patients with nonalcoholic fatty liver disease: a competing risk analysis (2021) (0)
- Response to Dr. Sertoglu and Colleagues (2015) (0)
- Reply: (2009) (0)
- Spontaneous and drug-induced histological changes in non-alcoholic steatohepatitis: an assessment by meta-analysis of trials (2022) (0)
- Reply: To PMID 24691835. (2015) (0)
- OC-06A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease (2021) (0)
- T06.01.12 OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY (2020) (0)
- AA genotype of deSNP rs6726639 of MERTK gene is associated with development of Hepatocellular Carcinoma after eradication of Hepatitis C Virus infection (2019) (0)
- Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease (2020) (0)
- Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆" [J Hepatol (2020) 505-515]. (2023) (0)
- 1137 LOW SERUM LEVELS OF LDL-CHOLESTEROL INVERSELY CORRELATE WITH OXYSTEROLS PLASMA LEVELS IN HCV INFECTED PATIENTS (2011) (0)
- Impact of Obesity and ALT Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in NAFLD Patients (2020) (0)
- P.127 HEPATIC STEATOSIS IS ASSOCIATED WITH SEVERE FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B (2010) (0)
- F.N.32 LIVER EXPRESSION OF RBP4 CORRELATES WITH LIVER DAMAGE IN CHRONIC HEPATITIS C AND IN NONALCOHOLIC FATTY LIVER DISEASE (2010) (0)
- 862 VISCERAL ADIPOSITY INDEX, EXPRESSION OF ADIPOSE DYSFUNCTION, IS ASSOCIATED WITH SIGNIFICANT FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (2011) (0)
- Survival and recurrences after curative treatments of HCV-related early hepatocellular carcinoma. A meta-analysis of single arm studies (2017) (0)
- The ART strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE (2014) (0)
- Italian Society of Obesity VIII National Congress (2016) (0)
- PNPLA3 rs738409 C > G SNP is associated with histological features of NASH in genotype 1 chronic hepatitis C patients (2014) (0)
- Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with mild-moderate fibrosis, with or without glucose abnormalities: interim results of the EGG18 study (2020) (0)
- Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with non-alcoholic fatty liver disease (2018) (0)
- Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with non-alcoholic fatty liver disease (2023) (0)
- Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression in patients with NAFLD (2016) (0)
- Reply (2016) (0)
- 918 HIGH SCD36 PLASMA LEVEL IS ASSOCIATED WITH STEATOSIS AND ITS SEVERITY IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C (2012) (0)
- SIRT5 rs12216101 T > G variant is associated with mitochondrial dysfunction and disease severity in patients with NAFLD (2022) (0)
- T06.01.15 IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION (2020) (0)
- Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study (2015) (0)
- LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS (2011) (0)
- Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis (2008) (0)
- Pharmacological interventions effect on liver histology in nonalcoholic steatohepatitis: a network meta-analysis (2022) (0)
- Hyperuricemia in non‐alcoholic fatty liver disease: authors’ reply (2011) (0)
- SIRT5 rs12216101 T>G variant is associated with oxidative stress and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease (2023) (0)
- OC.08.1 PROGRAMMED CELL DEATH 1 GENETIC VARIANT AND LIVER DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE (2023) (0)
- Virus-related insulin resistance in HCV genotype 1 chronic hepatitis C : a major disease modifier (2007) (0)
- Increased burden of inherited IRF3 rare genetic variants in Europeans with severe NAFLD (2022) (0)
- P848 Risk of Orthorexia Nervosa in Patients with Inflammatory Bowel Disease: A Link with Eating Disorders? (2023) (0)
- T.11.6 TREATMENT WITH GLECAPREVIR AND PIBRENTASVIR IS SAFE AND EFFECTIVE IN ITALIAN (2023) (0)
- AGILE-3 Score for the diagnosis of advanced fibrosis and for predicting liver-related events in nonalcoholic fatty liver disease (2022) (0)
- Prospective evaluation of screening strategies for NAFLD in people with type-2 diabetes mellitus in the community (2023) (0)
- Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease. (2023) (0)
- Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort (2022) (0)
- Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease (2023) (0)
- P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression (2022) (0)
- OC.03.2 THE PRESENCE OF WHITE MATTER LESIONS IS ASSOCIATED WITH THE HISTOLOGICAL SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Salvatore Petta?
Salvatore Petta is affiliated with the following schools:
